MetLife
MET
$85.85
-1.77%
MetLife, Inc. is a leading global provider of insurance, annuities, and employee benefit programs, operating primarily in the life insurance industry. As one of the largest life insurers in the US by assets, the company maintains a distinct competitive identity as a diversified, multinational player with significant earnings contributions from its US Group Benefits and Retirement segments, as well as established operations in Asia and Latin America. The current investor narrative centers on the company's ability to navigate a higher interest rate environment, which benefits its investment income, while managing the performance of its diverse international segments and executing on capital return initiatives, as evidenced by recent quarterly results showing substantial revenue growth.…
MET
MetLife
$85.85
Investment Opinion: Should I buy MET Today?
Rating: Hold. The core thesis is that MetLife presents a balanced risk/reward profile at current levels, with attractive long-term fundamentals offset by near-term technical resistance and margin concerns, warranting a wait-for-better-entry approach.
Supporting evidence includes a reasonable trailing PE of 15.53x, a deeply discounted forward PE of 8.08x implying strong earnings growth, and robust trailing FCF of $18.11B supporting a 3.2% dividend yield. The stock has shown exceptional relative strength, gaining 30.70% over three months versus the SPY's 12.0%. Analyst sentiment is constructive, with an implied target upside of 17-26% based on EPS estimates, though explicit price targets are scarce.
The thesis would upgrade to a Buy on a successful breakout above $89.44 with volume confirmation, signaling the technical resistance is overcome, or if the forward PE compressed further towards 7x without a deterioration in the earnings outlook. It would downgrade to a Sell if the stock fails at resistance and breaks below its 200-day moving average, or if Q1 2026 results show continued net margin compression below 3%. Relative to its own historical PE range (8.93x to 20.30x) and its strong FCF generation, the stock appears fairly valued to slightly undervalued, but the technical overbought condition near resistance tempers immediate enthusiasm.
Sign up to view all
MET 12-Month Price Forecast
The AI assessment is neutral based on conflicting signals: powerful momentum and attractive valuation are countered by profitability concerns and a key technical test. The low forward PE offers a margin of safety, but the stock needs to prove it can translate revenue growth into stable earnings. The stance would upgrade to bullish on a confirmed breakout above $89.44 coupled with evidence of margin stabilization in the next earnings report. It would turn bearish if the stock rejects the resistance level and falls below $80, which would break the short-term uptrend and suggest the recent rally was unsustainable.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on MetLife's 12-month outlook, with a consensus price target around $111.60 and implied upside of +30.0% versus the current price.
Average Target
$111.60
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$69 - $112
Analyst target range
Analyst coverage for MetLife appears limited based on the provided data, with only 5 analysts contributing to estimates for revenue and EPS, indicating this large-cap stock may have less concentrated institutional research focus than some peers. The consensus leans bullish, as evidenced by recent institutional ratings from firms like Morgan Stanley (Overweight), Wells Fargo (Overweight), and UBS (Buy), with no sell ratings noted in the recent actions list, though Evercore ISI maintains an 'In Line' rating. The target price range implied by EPS estimates is wide, with a low EPS estimate of $12.96 and a high of $13.86, translating to a price range of approximately $104 to $112 using the forward PE of 8.08x, suggesting a potential upside of 17% to 26% from the current price, but this is a derived range as explicit price targets are not provided in the data. The pattern of recent analyst actions shows stability, with all listed firms reiterating their existing ratings over the past several months, signaling sustained conviction and a lack of negative catalysts prompting downgrades.
Bulls vs Bears: MET Investment Factors
The evidence currently favors the bull case, driven by a powerful technical breakout, an attractive forward valuation, and strong free cash flow supporting capital returns. However, the bear case presents credible concerns regarding margin pressure and earnings volatility. The single most important tension in the investment debate is whether the company's significant net margin compression is a temporary phenomenon or a structural issue that will prevent it from capitalizing on its revenue growth and favorable interest rate environment. The resolution of this margin trend will be the key determinant of whether the stock can sustainably break above its 52-week high and re-rate higher.
Bullish
- Strong Technical Breakout Near 52-Week High: The stock is trading at $88.84, just below its 52-week high of $89.44, after a powerful 30.70% surge over the past three months. This momentum, coupled with a beta of 0.78 indicating the move has been less volatile than the market, suggests a sustainable bullish trend is in place.
- Attractive Forward Valuation at 8.08x PE: The forward PE ratio of 8.08x is significantly below the trailing PE of 15.53x, implying the market expects a substantial earnings increase. This valuation is reasonable for a large insurer and offers a margin of safety if earnings meet the analyst consensus EPS of $13.50.
- Robust Capital Return & Strong Free Cash Flow: The company generated $18.11 billion in trailing free cash flow, funding a consistent capital return program. In Q4 2025 alone, it paid $406M in dividends and repurchased $460M in stock, demonstrating a shareholder-friendly capital allocation policy.
- Solid Balance Sheet with Moderate Leverage: A debt-to-equity ratio of 0.71 indicates moderate and manageable leverage. Combined with a return on equity of 11.90%, this shows the company is using its capital efficiently while maintaining financial stability.
Bearish
- Significant Net Margin Compression: The quarterly net income margin compressed from 6.89% in Q4 2024 to 3.40% in Q4 2025, with net income falling from $1.27B to $809M year-over-year. This raises concerns about underlying profitability and cost management despite strong revenue growth.
- Volatile and Lumpy Revenue Recognition: While Q4 2025 revenue grew 29.14% YoY to $23.81B, it followed a Q3 revenue of $16.88B, highlighting the inherent volatility in insurance premium recognition. This makes consistent top-line growth difficult to assess and predict.
- Limited Analyst Coverage & Visibility: Only 5 analysts provide estimates for this large-cap stock, indicating lower institutional research focus and potentially less market efficiency. This can lead to higher volatility and mispricing due to information asymmetry.
- Technical Resistance at 52-Week High: The stock is trading at 97% of its 52-week range, facing immediate and significant resistance at $89.44. A failure to break through this level could trigger profit-taking and a consolidation, reversing the recent sharp gains.
MET Technical Analysis
The stock is in a sustained recovery trend, having gained 12.47% over the past year, but this masks significant volatility within the period. As of the latest close at $88.84, the price is trading near the top of its 52-week range, approximately 97% of the way from its 52-week low of $67.33 to its high of $89.44, indicating strong recent momentum and positioning the stock near a critical resistance level. The short-term momentum is exceptionally strong and accelerating, with the stock up 13.78% over the past month and 30.70% over the past three months, a stark reversal from the longer-term trend and suggesting a powerful bullish breakout is underway. This recent surge has pushed the price well above levels seen in early 2026, with the beta of 0.783 indicating the stock has been less volatile than the broader market during this advance, which is notable given the magnitude of the move. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $89.44 and major support at the 52-week low of $67.33; a confirmed breakout above $89.44 would signal a new bullish phase and likely target higher prices, while a failure here could lead to a consolidation. The stock's beta of 0.783 suggests it is approximately 22% less volatile than the S&P 500, which is typical for a large-cap financial but noteworthy given the stock's 30.70% 3-month surge compared to the SPY's 12.0% gain, highlighting its recent exceptional relative strength.
Beta
0.78
0.78x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$67-$90
Price range past year
Annual Return
+10.3%
Cumulative gain past year
| Period | MET Return | S&P 500 |
|---|---|---|
| 1m | +5.5% | +0.3% |
| 3m | +25.1% | +12.3% |
| 6m | +5.2% | +8.9% |
| 1y | +10.3% | +24.0% |
| ytd | +6.9% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MET Fundamental Analysis
Revenue growth has been volatile but showed a significant spike in the most recent quarter, with Q4 2025 revenue of $23.81 billion representing a 29.14% year-over-year increase; however, this follows a quarter (Q3 2025) where revenue was $16.88 billion, indicating lumpy premium recognition common in insurance. The gross margin for Q4 2025 was 30.53%, and the net income margin was 3.40%, derived from net income of $809 million on the $23.81 billion in revenue. Profitability remains intact but has shown some pressure, with net income of $809 million in Q4 2025 down from $1.27 billion in Q4 2024, and the quarterly net margin compressing from 6.89% to 3.40% year-over-year, though the company has remained consistently profitable across all provided quarters. The balance sheet and cash flow position appear solid, with a debt-to-equity ratio of 0.71 indicating moderate leverage, a return on equity of 11.90% demonstrating decent capital efficiency, and robust trailing twelve-month free cash flow of $18.11 billion providing ample internal funding for dividends, share buybacks, and growth initiatives. The current ratio of 0.65 suggests a liquidity profile typical for an insurance company where liabilities are largely long-term policy reserves, and the strong FCF supports the company's capital return program, as seen in the $406 million in dividends paid and $460 million in stock repurchased during Q4 2025.
Quarterly Revenue
$23.8B
2025-12
Revenue YoY Growth
+0.29%
YoY Comparison
Gross Margin
+0.30%
Latest Quarter
Free Cash Flow
$18.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MET Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 15.53x, while the forward PE is significantly lower at 8.08x, implying the market expects a substantial increase in earnings over the next year, which aligns with analyst EPS estimates averaging $13.50. Compared to sector averages, MetLife's trailing PE of 15.53x appears reasonable for a large, stable life insurer, though a direct industry average PE is not provided in the data for comparison; its Price-to-Sales ratio of 0.68x and Price-to-Book ratio of 1.85x suggest the market is valuing the company at a discount to its revenue and a modest premium to its book value. Historically, the stock's own trailing PE has fluctuated significantly, with a recent high of 20.30x in Q4 2023 and a low of 8.93x in Q1 2022; the current 15.53x sits roughly in the middle of this recent range, suggesting the market is pricing in a balanced view of earnings prospects without excessive optimism or pessimism relative to its own history.
PE
15.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability pressures and revenue volatility. The sharp year-over-year compression in Q4 net margin from 6.89% to 3.40% is a primary concern, indicating potential issues with claims experience, investment yields, or expense management. While revenue spiked 29% in the latest quarter, the preceding quarter was significantly lower, demonstrating the lumpy nature of insurance premiums which complicates earnings visibility. The company's moderate debt-to-equity of 0.71 is manageable, but its low current ratio of 0.65, while typical for insurers, requires careful asset-liability management.
Market & Competitive Risks include valuation re-rating and interest rate sensitivity. The stock's recent 30.70% surge in three months, far outpacing the SPY's 12.0% gain, may have priced in near-term optimism, increasing vulnerability to a pullback if momentum stalls at the $89.44 resistance. While the forward PE of 8.08x seems reasonable, it is predicated on a significant earnings jump; failure to meet the $13.50 EPS consensus could trigger multiple compression. As a life insurer, MetLife benefits from higher interest rates, but a sharp reversal in the rate cycle could pressure investment income. Competitive pressures in core markets like US Group Benefits and Asia could also impede growth.
Worst-Case Scenario involves a perfect storm of an earnings miss, a broader market downturn, and a sector rotation out of financials. This could break key technical support, leading to a sell-off towards the 52-week low of $67.33. Such a move would represent a downside of approximately -24% from the current price of $88.84. This scenario could be catalyzed by a larger-than-expected deterioration in underwriting results in a key segment like Asia, combined with rising credit losses in the investment portfolio, leading to analyst downgrades from the current bullish stance.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Continued net margin compression, as seen in the drop from 6.89% to 3.40% YoY in Q4, which could derail earnings growth. 2) Technical Risk: The stock is at major resistance ($89.44); a failure here could lead to a sharp reversal from recent 30.70% 3-month gains. 3) Macroeconomic Risk: Sensitivity to interest rates; a decline in rates would pressure investment income, a key earnings driver. 4) Geographic Concentration Risk: ~25% of earnings from Asia (mainly Japan), exposing the company to regional economic and currency headwinds.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $95 and $102, assuming it meets the $13.50 EPS consensus and consolidates recent gains. The Bull Case (30% probability) targets $104 to $112, requiring a breakout above resistance and earnings exceeding expectations. The Bear Case (20% probability) warns of a pullback to $67-$80 if margin pressures worsen and technical support fails. The most likely outcome is the Base Case, hinging on the assumption that the company stabilizes its profitability in the coming quarters.
MET appears fairly valued to slightly undervalued based on forward earnings. Its trailing PE of 15.53x is in the middle of its own recent historical range (8.93x to 20.30x). The more telling metric is the forward PE of 8.08x, which is low and suggests the market is not fully pricing in the expected earnings growth. Compared to sector averages, its Price-to-Sales of 0.68x and Price-to-Book of 1.85x do not suggest overvaluation. The valuation implies the market expects earnings to recover but remains skeptical due to margin volatility, creating a potential opportunity if that skepticism proves overdone.
MET is a conditional buy for patient, value-oriented investors. The forward PE of 8.08x is compelling if the company meets its $13.50 EPS consensus, implying significant upside. However, the stock is at a critical technical juncture, testing its 52-week high of $89.44, and recent margin compression is a concern. For investors comfortable with financial sector exposure, it could be a good buy on a pullback to the low $80s or a confirmed breakout above $89.44. The robust free cash flow and shareholder returns provide a solid foundation, but timing the entry is key given the recent sharp run-up.
MET is more suitable for a long-term (3+ years) investment horizon. Its value proposition is based on steady capital returns (dividend and buybacks) and earnings growth realization, which takes time. The stock's beta of 0.78 indicates lower volatility than the market, aligning with a core holding rather than a trading vehicle. However, short-term traders might find opportunities around earnings volatility and technical levels. Given the need to monitor the resolution of margin trends and the technical breakout attempt, a minimum holding period of 12-18 months is suggested to allow the investment thesis to play out.